BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37863329)

  • 1. NLRP3 inflammasome in hepatic diseases: A pharmacological target.
    Ramos-Tovar E; Muriel P
    Biochem Pharmacol; 2023 Nov; 217():115861. PubMed ID: 37863329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.
    Gaul S; Leszczynska A; Alegre F; Kaufmann B; Johnson CD; Adams LA; Wree A; Damm G; Seehofer D; Calvente CJ; Povero D; Kisseleva T; Eguchi A; McGeough MD; Hoffman HM; Pelegrin P; Laufs U; Feldstein AE
    J Hepatol; 2021 Jan; 74(1):156-167. PubMed ID: 32763266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation.
    Liu J; Wang T; He K; Xu M; Gong JP
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8158-8167. PubMed ID: 31599445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
    J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-specific Deletion of NLRP3 Inflammasome Identifies Myeloid Cells as Key Drivers of Liver Inflammation and Fibrosis in Murine Steatohepatitis.
    Kaufmann B; Kui L; Reca A; Leszczynska A; Kim AD; Booshehri LM; Wree A; Friess H; Hartmann D; Broderick L; Hoffman HM; Feldstein AE
    Cell Mol Gastroenterol Hepatol; 2022; 14(4):751-767. PubMed ID: 35787975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis.
    Povero D; Lazic M; McBride C; Ambrus-Aikelin G; Stansfield R; Johnson CD; Santini AM; Pranadinata RF; McGeough MD; Stafford JA; Hoffman HM; Feldstein AE; Veal JM; Bain G
    J Pharmacol Exp Ther; 2023 Aug; 386(2):242-258. PubMed ID: 37308266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis.
    Torres S; Segalés P; García-Ruiz C; Fernández-Checa JC
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
    Wree A; McGeough MD; Peña CA; Schlattjan M; Li H; Inzaugarat ME; Messer K; Canbay A; Hoffman HM; Feldstein AE
    J Mol Med (Berl); 2014 Oct; 92(10):1069-82. PubMed ID: 24861026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
    He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
    Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis.
    Knorr J; Wree A; Tacke F; Feldstein AE
    Semin Liver Dis; 2020 Aug; 40(3):298-306. PubMed ID: 32526788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panaxydol extracted from Panax ginseng inhibits NLRP3 inflammasome activation to ameliorate NASH-induced liver injury.
    Kim MY; Jeong B; Lee GS; Jeon H; Yang YM; Yang H; Han YH
    Int Immunopharmacol; 2024 Feb; 128():111565. PubMed ID: 38262161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NLRP3 Inflammasome Formation and Activation in Nonalcoholic Steatohepatitis: Therapeutic Target for Antimetabolic Syndrome Remedy FTZ.
    Chen Y; He X; Yuan X; Hong J; Bhat O; Li G; Li PL; Guo J
    Oxid Med Cell Longev; 2018; 2018():2901871. PubMed ID: 30140364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dehydromevalonolactone ameliorates liver fibrosis and inflammation by repressing activation of NLRP3 inflammasome.
    Niu WX; Bao YY; Zhang N; Lu ZN; Ge MX; Li YM; Li Y; Chen MH; He HW
    Bioorg Chem; 2022 Oct; 127():105971. PubMed ID: 35749855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin.
    Yang W; Liu L; Wei Y; Fang C; Liu S; Zhou F; Li Y; Zhao G; Guo Z; Luo Y; Li L
    Lab Invest; 2021 Mar; 101(3):369-380. PubMed ID: 33268842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis.
    Zhang NP; Liu XJ; Xie L; Shen XZ; Wu J
    Lab Invest; 2019 Jun; 99(6):749-763. PubMed ID: 30700851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH.
    Wan X; Xu C; Yu C; Li Y
    Can J Gastroenterol Hepatol; 2016; 2016():6489012. PubMed ID: 27446858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bee's honey attenuates non-alcoholic steatohepatitis-induced hepatic injury through the regulation of thioredoxin-interacting protein-NLRP3 inflammasome pathway.
    Xiao J; Liu Y; Xing F; Leung TM; Liong EC; Tipoe GL
    Eur J Nutr; 2016 Jun; 55(4):1465-77. PubMed ID: 26133299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice.
    Lebeaupin C; Vallée D; Rousseau D; Patouraux S; Bonnafous S; Adam G; Luciano F; Luci C; Anty R; Iannelli A; Marchetti S; Kroemer G; Lacas-Gervais S; Tran A; Gual P; Bailly-Maitre B
    Hepatology; 2018 Aug; 68(2):515-532. PubMed ID: 29457838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release.
    Pan J; Ou Z; Cai C; Li P; Gong J; Ruan XZ; He K
    Cell Immunol; 2018 Oct; 332():111-120. PubMed ID: 30103942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation.
    Tang Y; Cao G; Min X; Wang T; Sun S; Du X; Zhang W
    J Physiol Biochem; 2018 Nov; 74(4):503-510. PubMed ID: 30019185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.